Caribou Biosciences vs Zenas Biopharma
Caribou Biosciences and Zenas Biopharma are similar in size: $11.2m and $10.0m of revenue in their latest fiscal years. Zenas Biopharma grew faster (100.0% against 11.7%). Caribou Biosciences kept more of each dollar of sales as profit: a net margin of -1327.4% against -3777.4%. Caribou Biosciences carries less debt relative to equity (0.0% against 32.5%).
| Latest fiscal year | Caribou BiosciencesCRBU, 2025 | Zenas BiopharmaZBIO, 2025 |
|---|---|---|
| Revenue | $11.2m | $10.0m |
| Revenue growth | 11.7% | 100.0% |
| Net income | −$148m | −$378m |
| Operating margin | -1329.4% | -3830.6% |
| Net margin | -1327.4% | -3777.4% |
| Return on equity | -79.0% | -136.2% |
| Free cash flow | −$112m | −$172m |
| Cash | $12.4m | $111m |
| Total debt | $0 | $78.6m |
| Debt to equity | 0.0% | 32.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 167 |
| Market value | $47.4m | $1.79bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 5 sales | 17 buys, 0 sales |